

540,968

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau(43) International Publication Date  
23 June 2005 (23.06.2005)

PCT

(10) International Publication Number  
**WO 2005/057436 A1**(51) International Patent Classification<sup>7</sup>: **G06F 17/50**,  
A01N 63/00, B29C 41/00Saif [EG/US]; 138 Hamlet Drive, King of Prussia, PA  
19406 (US).(21) International Application Number:  
PCT/US2004/015316(74) Agents: **LICATA, Jane, Massey. et al.**; Licata & Tyrrell  
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(22) International Filing Date: 14 May 2004 (14.05.2004)

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:  
60/520,272 14 November 2003 (14.11.2003) US(71) Applicant (for all designated States except US): **DREXEL  
UNIVERSITY** [US/US]; 32nd and Chestnut Streets,  
Philadelphia, PA 19104 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SUN, Wei** [US/US];  
5 Todd Court, Cherry Hill, NJ 08003 (US). **NAM, Jae,  
Hyun** [US/US]; 2709 S. Kent Road, Broomall, PA 19008  
(US). **DARLING, Andrew, Leete** [US/US]; 3841 Hamil-  
ton Street, #3, Philadelphia, PA 19104 (US). **KHALIL,**(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHOD AND APPARATUS FOR COMPUTER-AIDED TISSUE ENGINEERING FOR MODELING, DESIGN  
AND FREEFORM FABRICATION OF TISSUE SCAFFOLDS, CONSTRUCTS, AND DEVICES

(57) Abstract: A process and apparatus are provided for manufacturing complex parts and devices which utilize a CAD environment to design a part or device to be created (Figure 1); Boolean, scaling, smoothing, mirroring, or other operations to modify the CAD design; a software interface to convert the CAD designed part (Data Process System) or device into a heterogeneous material and multi-part assembly model (Design Input Model) which can be used for multi-nozzle printing; and a multi-nozzle system to print the designed part or device using different, specialized nozzles (Tissue substitutes).

WO 2005/057436 A1



**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Methods and Apparatus for Computer-Aided Tissue Engineering  
for Modeling, Design and Freeform Fabrication of Tissue  
Scaffolds, Constructs, and Devices**

5        This patent application claims priority to U.S.  
Provisional patent application Serial No. 60/520,272, filed  
November 14, 2003, which is herein incorporated by  
reference in its entirety.

**Field of the Invention**

10        The present invention provides methods and apparatus  
for manufacturing complex devices for use in areas  
including, but not limited to, tissue engineering,  
organ/cell printing, tissue scaffolds, tissue cultures,  
biochips, biosensors, cytotoxicity test samples, and other  
15 fields that are currently limited by conventional methods  
of manufacture. The present invention provides methods and  
apparatus which integrate computer-aided design; Boolean,  
scaling, mirroring, smoothing, and/or other modifying  
operations; Magnetic Resonance Imaging (MRI)/ Computed  
20 Tomography(CT) and other patient specific data import  
capabilities; heterogeneous material and multi-part  
assembly capabilities; biomimetic and non-biomimetic design  
capabilities; multiple types of nozzles capable of handling  
a wide range of materials as well as multiple modes of  
25 nozzle operation such as droplet deposition, extrusion, and  
spraying; and/or a biologically friendly design capable of  
direct cell deposition, to create a very powerful and  
versatile manufacturing process. Further, these methods and  
apparatus provide for simultaneous deposition of cells with  
30 scaffolding materials to form cell-seeded tissue  
substitutes. Accordingly, the methods and apparatus of the  
present invention permit construction of complex or smart  
tissue scaffolds capable of eliciting complex behaviors of  
cells including, but not limited, to growth, migration,  
35 differentiation, and expression. Tissue engineering

scaffolds produced in accordance with the methods and/or using the devices of the present invention can also assist with the flow and transport of vital nutrients and oxygen, and the removal of waste products required by cells seeded  
5 within the scaffolds.

### Background of the Invention

Most tissue engineering techniques basically consist of seeding a tissue scaffold or culture dish with cells that are grown in an incubator. The scaffold fabrication  
10 and the cell seeding are two separate processes. These techniques are very limited in their level of sophistication. The scaffolds tend to be simple structures made out of a single material, with some post-processing techniques in the slightly more complicated scaffolds.  
15 Organized, heterogeneous cellular structures are very difficult to create, and impossible to create at the complexity level of an organ using standard techniques. Seeding these kinds of scaffolds may not be enough to stimulate the cells into responding in the desired manner.  
20 A complex scaffold is required to elicit complex behavior from a cell. A new generation of tissue scaffolds is required to take the next step in tissue engineering which essentially moves away from simple scaffolds toward complex scaffolds. A cell is a very sophisticated machine with  
25 programming built into its genetic code. A complex scaffold takes advantage of this built-in programming through the incorporation of various biological factors that direct cell growth, migration, differentiation, and expression. In addition, constructs can be created that could help with  
30 the flow and transport of vital nutrients and oxygen, and the removal of waste products.

Layered manufacturing has been suggested as being well suited to the field of biology. This has resulted in much research being conducted within the field of computer-  
35 aided tissue engineering (CATE). Unfortunately, many Solid

Freeform Fabrication (SFF) techniques are not biologically friendly using techniques that cannot handle a wide range of wet materials, gels or solutions. Also, many SFF techniques utilize harsh solvents, high temperatures, high pressures, and other factors that are not conducive to biological systems. Many SFF techniques, such as stereolithography, fused deposition methods, and powder/binder-based techniques, are capable of creating tissue scaffolds, but cannot directly deposit cells or biological factors into the scaffold. This has resulted in the creation of different techniques to handle direct cell deposition.

Weiss, et al. have described a method for building bone tissue scaffolds using SFF (Reischmann et al. *Electrotechnik und Informationstechnik* 2002 7/8:248-252; Weiss et al. *Journal of Manufacturing Systems* 1997-16(4): 239-248). This process consists of taking a CAD model of a three-dimensional structure of a bone implant, slicing the model into layers, taking laminated sheets of scaffold material, seeding the layers with cells or growth factors, and stacking them on top of each other. This process was designed for the purpose of constructing bone implants, not to provide a flexible process of creating various types of organs or biologically/chemically integrated systems and thus has several disadvantages with respect to construction of tissue engineering devices. For example, the method is limited in materials since soft, gel-like materials cannot be used as scaffold layers. This is a problem since many biological parts are soft or wet. Also, each layer of the scaffold is made with one type of sheet material. Thus, it is difficult to have two or more different materials within the same layer level. Accuracy and recalibration is an issue as well since the scaffold layers are moved from station to station. Thus, although a simple scaffold can be created by this method, a complex scaffold with

controlled concentration gradients is difficult, if not impossible, to create. This is a serious disadvantage since cells are very responsive to even the slightest differences in concentration gradients.

5       Yan and Xiong, et al. have disclosed the concept of using layered manufacturing methods and multi-nozzle deposition extrusion and jetting processes (Xiong et al. *Scripta Materialia* 2002 46:771-776; Yan et al. *Materials Letters* 2003 57:2623-2628). Their process includes  
10 spraying and deposition of heterogeneous materials with different material properties. However, full CAD integration is not described. Nor is there any description of the ability to import an assembly of multiple STL files for printing a complex, heterogeneous, three-dimensional  
15 structure. This is a vital design component when building complex parts such as biomimetic parts where MRI or CT data is incorporated into the final design, or integrating both biomimetic parts and non-biomimetic parts into a novel scaffold design.

20       A SFF method using a syringe-based system to dispense liquids, which is well suited for working with biological materials such as cells and hydrogels has also been described (Landers et al. *Macromol Mater Eng* 2000 282:17-21; Landers et al. *Kunststoffe/plast Europe* 2001 91(12):  
25 21-23; Landers et al. *Biomaterials* 2002 23:4437-4447). The primary focus of this method is the building of scaffolds and seeding the scaffold. The deposition system used is a single nozzle device that requires cartridge swapping to change materials. This is not a very practical system for  
30 depositing multiple, heterogeneous materials such as different types of cells and growth factors all within the same scaffold layer. Further, it is difficult to take a multiple part assembly of STL files and print out a complex, biologically designed scaffold utilizing this

method. Thus, there are limitations in this method with respect to the CAD integration aspect as well.

A syringe-based system for the extrusion of hybrid polymer materials embedded with glass using layered SFF manufacturing has also been described (Calvert et al. *Materials Science and Engineering* 1998 C6:167-174). This system also uses a single nozzle and does not incorporate CAD, thus being limited to simple designs written in Microsoft Qbasic. This system is not capable of creating heterogeneous designs within a single layer. Thus, this system is sufficient for creating basic scaffolds, but falls short of being able to create intricate scaffolds containing both biomimetic and non-biomimetic features.

A microsyringe deposition system has also been described (Vozzi et al. *Materials Science and Engineering* 2002 C20:43-47; Vozzi et al. *Biomaterials* 2003 24:2533-2540). This system utilizes a single-nozzle deposition system which has fine resolution, but is limited because of the glass capillary used for deposition. The glass capillary limits the range of viscosities that are usable due to pressure limits, and also limits the types of solutions and suspensions that can be deposited due to clogging. The device is envisaged for integration with CAD, but whether their working device could actually utilize STL files is unclear. Also, the single nozzle system makes multi-material, heterogeneous deposition difficult.

A single-nozzle, automated extrusion system that can utilize basic STL files has been described as well (Ang et al. *Materials Science and Engineering* 2002; C20:35-42). It is unclear whether this system can be utilized to produce multi-part, heterogeneous STL files. This single nozzle process also makes constructing complex parts very difficult, and limits the diverse range of materials available for deposition.

Mironov, et al. discuss the basic principles of organ printing, which involves direct deposition of cells using a multi-nozzle printing system (Mironov et al. TRENDS in Biotechnology 2003 21(4):157-161). A general basic concept of organ printing involving CAD in the preprocessing stage incorporating either patient specific MRI/CT data or artificial computer generated biomimetic constructs is set forth. However, there is no mention of the value of CAD beyond simply imitating biology. In addition, there are serious limitations with their disclosed multi-nozzle system which uses the same type of syringe thus limiting the types of materials that can be deposited. In order to build good 3-dimensional structures, relatively viscous solutions are required, which means high pressure. High pressure, however, may not be compatible with cells. High pressure systems handling viscous materials have the problem of not being able to deposit fine structures with fine concentration gradients. Finally, there is a flaw in the process described in this reference because they do not consider the fact that CAD programs do not have heterogeneous material capabilities. Thus, they neglect a non-trivial and difficult step by assuming that they can create a multi-material part in CAD and print it out using multiple nozzles, which is not necessarily the case.

U.S. Patent 6,139,574 (Vacanti, et al. October 31, 2000) discloses vascularized tissue regeneration matrices formed by SFF techniques. Use of CAD and SFF techniques for the creation of tissue scaffolds is mentioned. Further, they mention the possibility of using multiple printheads and different kinds of SFF techniques. However, there is no description of direct cell deposition. The reason for this is that the method described is not biologically friendly to cells. Thus, the described method requires depositing the scaffold material and bioactive materials first to create the scaffold, and then seeding

the cells externally relying upon cell migration to populate the scaffold. Further, the inkjet printing method described by Vacanti creates problems for cellular deposition unless significant steps are taken to protect  
5 cells from shear stresses that would tear the cell apart.

U.S. Patent 6,143,293 (Weiss, et al. November 7, 2000) discloses assembled scaffolds for three dimensional cell culturing and tissue generation. The method used is primarily oriented towards building hard, bone-type  
10 scaffold structures and creation of soft, gel-like scaffolds using this method may be difficult. Further heterogeneous capabilities are limited to materials that can be added on top of the layer, but not within the layer itself. The method of Weiss et al. also utilizes  
15 prefabricated layers thus necessitating an assembly stage, which then requires extra steps to calibrate, align, and affix the layers. Means for affixing the layers such as barbs, or other mechanical affixing means is a disadvantage that may result in later complications due to wear, bone  
20 remodeling, or incompatibilities in material properties. The method described by Weiss et al. thus lacks versatility and flexibility.

U.S. Patent 6,027,744 and U.S. Patent 6,171,610 (Vacanti, et al. February 22, 2000 and Vacanti, et al.  
25 January 9, 2001) describe guided development and support of hydrogel-cell compositions. Methods described therein use hydrogel-cell compositions as a means of tissue scaffold construction and rely upon injecting the hydrogel-cell material into the tissue scaffold. The described method  
30 does not include layered fabrication methods or CAD. Direct deposition of cells into a scaffold while constructing the scaffold is also not mentioned.

U.S. Patent 6,176,874 (Vacanti, et al. January 23, 2001) discloses vascularized tissue regeneration matrices  
35 formed by SFF fabrication techniques. Again, the described

method does not include layered fabrication methods or CAD nor direct deposition of cells into a scaffold while constructing the scaffold.

U.S. Patent 6,454,811 (Sherwood, et al. September 24,  
5 2002) discloses composites for tissue regeneration and methods of manufacture thereof. This method primarily focuses on three-dimensional printing (3DP) for tissue engineering. Although there is mention that other methods of SFF could be used, no explicit details are provided.  
10 Further, there is no mention of CAD integration, heterogeneous materials, multi-part assemblies, and multi-nozzle printing within a CAD environment. In addition, the majority of the SFF methods described are not biologically friendly for direct cell deposition. For example, stereo-  
15 lithography, selective laser sintering, and fused deposition modeling cannot directly deposit cells due to heating and toxicity issues which will kill cells. Ballistic particle manufacturing also has problems due to shear stresses that can damage cells, which are very  
20 sensitive and require low pressure or a protective method to reduce the shear stresses experienced by the cell. The described 3DP method is also unable to directly seed cells into the interior of the part that is being constructed. This process also requires post-processing in which powder,  
25 which functions both as the part and the support material, has to be removed after finishing the printing process. Thus, while this method can be used to create porous structures, the pores are filled with powder during the printing stage. It is only after printing has been  
30 completed that the powder is removed to open up the pores. Thus, cells cannot be directly printed at specific locations inside the part. Instead, cells must migrate from the outside of the scaffold, into the interior of the scaffold. This is a serious disadvantage when trying to  
35 create reproducibility between histotypic or organ culture

samples. Finer features require additional post-processing, such as salt-leaching, which again makes direct cellular deposition impossible.

U.S. Patent 6,547,994 (Monkhouse, et al. April 15,  
5 2003) describes a process for rapid prototyping and manufacturing of primarily drug delivery systems with multiple gradients, primarily involving a 3DP technique. These 3DP techniques share the same shortcomings as described for U.S. Patent 6,454,811.

10 U.S. Patent 6,623,687 (Gervasi, et al. September 23, 2003) describes a process for producing three-dimensional objects by constructing an interlaced lattice construct using SFF to create a functional gradient material. There is brief mention of the possibility of using this technique  
15 to create tissue engineered constructs such as veins and arteries. However, there is no demonstration of use in this application.

#### Summary of the Invention

An aspect of the present invention is related to a  
20 method for production of complex components or parts and devices used, for example, as tissue scaffolds and constructs. The method of the present invention integrates computer-aided design; Boolean, scaling, mirroring, smoothing, and/or other modifying operations; MRI/CT and  
25 other patient specific data import capabilities; heterogeneous material and multi-part assembly capabilities; biomimetic and non-biomimetic design capabilities; multiple types of nozzles capable of handling a wide range of materials; multiple modes of nozzle  
30 operation such as droplet deposition, extrusion, and spraying; and/or a biologically friendly design capable of direct cell deposition. Components and devices produced in accordance with the method of the present invention are useful, for example, in tissue engineering, organ/cell

printing, tissue scaffolds, tissue cultures, biochips, biosensors, and cytotoxicity test samples

Another aspect of the present invention is related to an apparatus or system for production of devices requiring the integration of different biological elements such as an artificial organ and/or devices requiring integration of biological and artificial elements. The apparatus comprises a multi-nozzle biopolymer deposition system capable of extruding biopolymer solutions and living cells for freeform construction of three-dimensional tissue scaffolds. The apparatus can, simultaneously with the scaffold construction, deposit controlled amount of cells, growth factors, or other bioactive compounds with precise spatial position to form well-defined cell-seeded tissue constructs. The apparatus or system also enables the fabrication of larger or thicker tissue constructs with complex layouts, such as vascular networks.

#### **Brief Description of the Figures**

Figure 1 provides a flow diagram of a system configuration of a multi-nozzle biopolymer deposition apparatus of the present invention.

Figure 2 provides a photograph of an exemplary multi-nozzle biopolymer deposition apparatus of the present invention.

Figures 3a through 3c show the creation of a multi-layered scaffold in accordance with the present invention to design a porous channel structure as a CAD model (Figure 3a), and use of patient specific MRI/CT data to design the required anatomical replacement scaffold model (Figure 3b), and further use of Boolean operation to produce a porous, interconnected replacement scaffold as the finished implant (Figure 3c).

Figures 4a through 4d show the creation of a triple-layered scaffold produced in accordance with the same techniques as set forth in Figure 4a through 4c. Figure 4a

shows the initial CAD model, followed by creation of porous outer layer (Figure 4b), and subsequent creation of a compact middle layer (Figure 4c). Figure 4d shows a cutaway view of the finished triple layer implant with porous inner layer.

Figures 5a through 5c show creation of an exemplary replacement scaffold in accordance with the present invention wherein CAD-MRI/CT and Boolean operations are combined to introduce a pre-designed structural feature into the replacement scaffold. In this example, a vascular tree was created in CAD that followed a basic pathway analogous to artery - arteriole - capillary - venule - vein (Figure 5a). Using scaling and Boolean operations a portion of an implant was quickly "vascularized" (Figure 5b-c). CATE to was used to create channels in an implant. Figure 5a shows the vascular tree created in CAD. As shown in Figure 5b, the CAD design was imported and rescaled as STL files in Geomagic (a reverse engineering software). Figure 5c shows the scaffold structure after Boolean operation.

Figure 6a through 6d shows creation of a tissue scaffold designed with built-in functional components that are non-biological in nature. In this example, a drug chamber was designed in CAD (Figure 6a). This feature was then added to the scaffold. Figure 6b shows the scaffold before subtraction of the chamber insert from the scaffold and Figure 6c shows the scaffold following chamber insertion. An existing vascular tree design was also incorporated into the scaffold as shown in the cutaway of Figure 6d, which depicts both the chamber and channels of this integrated delivery system.

Figure 7a through 7c shows various three-dimensional hydrogel scaffolds produced with the methods and apparatus of the present invention. Figure 7a and b show a three-dimensional hydrogel scaffold comprising 10 layers of

calcium alginate, extruded as a 3% (w/v) alginate filament within a cross-linking solution (Figure 7a) and simple alginate geometrical pattern (Figure 7b). By varying the size of the syringe nozzle, the pressures used, and the type of deposition method (extrusion), alginate filaments within the 30-40 micron range (Figure 7c) for 3% (w/v) sodium alginate solution with a 5% (w/v) calcium chloride cross-linking solution, at 0.50 psi were produced.

Figure 8 shows results of a cell deposition/extrusion study conducted using a hydrogel produced with the apparatus and method of the present invention. For these experiments, the hydrogel was produced from alginate hydrogel mixed with human endothelial cells at a cell concentration 750,000 cells/ml with sodium alginate: 1.5% (w/v), nozzle: EFD 200  $\mu$ m at pressure: 2 psi, deposition speed: 10 mm/s, and calcium chloride: 5% (w/v).

Figure 9 shows a hydrogel from similar experiments to those depicted in Figure 8 wherein multi-nozzle heterogeneous deposition of different materials was used to produce the hydrogel. As shown in Figure 9, a variety of materials were simultaneously deposited, containing different alginate solutions at concentrations in the range of 0.1% - 0.4% (w/v), with the lighter gray material (indicated by A) also containing an alginate microspheres suspension and a darker gray (indicated by B) chitosan hydrogel.

#### Detailed Description of the Invention

There is a vital demand for improving tissue engineering techniques. Organ transplantation and the need for donors is a problem within this country. With increasing life expectancy and a growing aging population, the need for organ transplantation is ever greater. However, there is currently no process capable of creating seeded tissue scaffolds for implantation with the complexity of organs.

In addition to organ transplantation, there is a need for improved methods of cytotoxicity testing for the pharmaceutical, cosmetics, and food industries. This would help resolve the ethical problem of animal testing, and in  
5 a more practical sense, also help reduce cost as well. Creating sophisticated, three-dimensional organ cultures could replace simple two-dimensional cultures that are not necessarily reliable in determining cytotoxicity. In addition, organ culture, organotypic cultures, and  
10 histotypic cultures are not easily standardizable. By having an automated manufacturing process for creating artificial organ cultures, there would be standardization, and the ability to compare experimental results between different organ cultures.

15 In addition to the need for organs and better methods of cytotoxicity testing, there are also the developing areas of biochips, bioelectronics, biosensors, bionics, cybernetics, artificial organs, and bioactive tissue scaffolds. These devices require the integration of both  
20 biological and artificial elements. Any device that could improve this integration would be a significant advance to those fields.

The present invention provides methods and systems for producing devices that can satisfy the above described  
25 need.

Figure 1 shows a flow diagram of a system configuration of a multi-nozzle biopolymer deposition apparatus of the present invention.

As shown in Figure 1, in the methods and apparatus of  
30 the present invention, a data processing system processes a designed scaffold model and converts it into a layered process tool path.

The apparatus further comprises a motion control system driven by this layered manufacturing technique.

The material delivery system for the apparatus comprises multiple nozzles of different types and sizes, thus enabling the deposition of specified hydrogels with different viscosities for constructing three-dimensional tissue scaffolds. In a preferred embodiment, four types of nozzles are used in the system or apparatus. Examples include, but are not limited to, solenoid-actuated nozzles, piezoelectric glass capillary nozzles, pneumatic syringe nozzles, and spray nozzles, with size ranges varying from about 30  $\mu\text{m}$  to about 500  $\mu\text{m}$ . The system can continuously extrude hydrogels, or form hydrogels in single droplets with picoliter volumes. The multiple nozzle capability allows for simultaneous deposition of cells, growth factors, and scaffold materials, thus enabling the construction of heterogeneous scaffolds with bioactive compounds, or establishing functional gradient scaffolds with different mechanical/structural properties in different scaffold regions.

Figure 2 provides a photograph an exemplary multi-nozzle biopolymer deposition apparatus of the present invention.

Step one of the methods and apparatus of the present invention comprise integrated computer-aided design capabilities. The methods and system of the present invention may further comprise as step two MRI/CT and other patient specific data import capabilities thereby allowing adaptation of each manufactured part for each person's unique geometry.

CAD provides the user with the basic ability to create both biomimetic and non-biomimetic designs and features. These can be created by the deposition of electrically conductive materials, magnetic materials, thermally conductive materials, mechanically active materials, bioactive elements, genetic materials and vectors, and so forth.

For example, as shown in Figure 3a through 3c, CAD can be used to design a porous channel structure as a CAD model (Figure 3a). Patient specific MRI/CT data is then used to design the required anatomical replacement scaffold  
5 model (Figure 3b). Boolean operation is then used to produce a porous, interconnected replacement scaffold (Figure 3c).

As shown in Figure 4a through 4d, using these same simple methodologies of the present invention, a triple-  
10 layered structure with a porous outer layer, a compact middle layer, and a porous inner layer is created.

Further, as shown in Figure 5a through 5c, CAD-MRI/CT and Boolean operations can be combined in accordance with the present invention to introduce a pre-designed structure  
15 feature into a scaffold such as replacement scaffold. For example, as shown in Figure 5, a vascular tree can be created in CAD that follows a basic pathway analogous to artery - arteriole - capillary - venule - vein (Figure 5a). Using scaling and Boolean operations a portion of an  
20 implant can then be quickly "vascularized".

With power of the computer-aided tissue engineering, tissue scaffolds can be designed with built-in functional components that are non-biological in nature. For example, growth factors and drugs play vital roles in tissue  
25 engineering. Accordingly, a drug chamber for storage and delivery of such agents can be designed in CAD (Figure 6a) and then added as a feature to the scaffold (Figure 6b-d). As shown in Figure 6d, an existing vascular tree design was also incorporated into the scaffold. Other non-biomimetic  
30 features such as inlet and outlet ports and attachment interfaces can be added in similar fashion thus allowing for quick assembly of sophisticated scaffolds using the methods and apparatus of the present invention.

As shown by these exemplary scaffold embodiments of  
35 Figures 3 through 6, following CAD design, the methods and

the apparatus of the present invention may further comprise Boolean, scaling, smoothing, mirroring, and/or other modifying operations which can be used to design and incorporate biomimetic and non-biomimetic features. Thus, 5 step two of the method of the present invention may comprise use of Boolean, scaling, smoothing, mirroring, and/or other operations to modify the design. A combination of these types of operations adds great versatility to the design process. Examples of Boolean 10 operations are addition and subtraction operations used to create voids or parts that fill voids, conforming to their geometry and anatomical shape. Boolean additive and subtractive capabilities also allows the operator to create a set of standardized or "stock" parts and features that 15 can be reused and recycled in multiple designs. While such operations can be skipped when creating relatively simple devices, when building complex devices, use of one or more of these operations are extremely useful and expand the design capabilities immensely.

20 The ability to create both biomimetic and non-biomimetic features permits one of skill in the art to produce a device such as a scaffold comprising, for example, electrically conductive materials, magnetic materials, thermally conductive materials and mechanically 25 active materials as well as bioactive elements, genetic materials and vectors. Examples of non-biomimetic features which can be incorporated into devices produced by this method and apparatus include, but are not limited to, electrically conductive material deposited, extruded, laid 30 down, in order to create wires, circuits, biochips, etc., mechanically active elements such as microvalves or miniature pumps and actuators built or incorporated into the finished part to create a microfluidic device, biochip, biosensor, a specialized component or prefabricated 35 element, such as an integrated circuit, valve, or

piezoelectric element added through an automated device that is designed to place it into the part being constructed, a tip or other device used to direct electrical stimulation or to apply a charge to direct ion  
5 flow, stimulate muscle contraction, cause changes to the cell nucleus, and a tip or device with a voltage potential between the tip and substrate in order to deposit material onto the substrate via a process similar to electrosinning.

10 The methods and apparatus of the present invention may further comprise multi-nozzle capability thus permitting deposit of multiple materials within the same layer. Different types of specialized nozzles provide versatility to the process of the present invention to  
15 handle a wide range of materials such as suspensions, gels, and a wide range of viscosities ranging from water to viscous glues. Further, multiple modes of nozzle operation can be provided including, but not limited to, droplet deposition, extrusion, and spraying operations, thereby  
20 allowing control of different levels of resolution and material properties. For example, fine microdroplet deposition may be used for adding minute concentrations of biological factors, and extrusion may be used to create a strong scaffold structure.

25 Accordingly, in step three of the method and apparatus of the present invention, interface software is used to convert the CAD designed device of step 1 or steps 1 and 2 into a heterogeneous material and multi-part assembly model that can be used for multi-nozzle printing.  
30 This is an important step of the method as it allows the user to take a multi-material CAD design and print it out using multiple nozzles.

The methods and apparatus of the present invention may further comprise heterogeneous material and multi-part  
35 assembly capabilities so that in step four of the method of

the present invention the design is printed out using the different, specialized nozzles. This step also vastly increases the repertoire of materials that are usable, and thus expands the type of designs that can be built, ranging  
5 for example from biological to non-biological scaffolds, parts, devices, etc. The nozzles are also capable of handling multiple modes of nozzle operation such as droplet deposition, extrusion, and spraying, thus allowing for control of different levels of resolution and material  
10 properties. A very important ability of the process of the present invention is direct seeding of a part without having to rely upon cellular ingrowth or migration to reach the interior of the part due to the precision deposition of the seeding materials.

15 Exemplary hydrogels depicting versatility achieved through use of the apparatus and methods of the present invention are depicted in Figures 7 through 9.

As can be seen, using the method and system of the present invention a complex, multi-material CAD design can  
20 be printed out using multiple nozzles. This is a significant advantage of the methods and system of the present invention that cannot be accomplished using CAD and solid modeling programs incapable of modeling heterogeneous parts with different material properties.

25 The methods and system of the present invention utilize biologically friendly design capabilities so that cells and/or biological factors can be deposited directly within and/or onto the scaffold.

Direct cell deposition is a very important capability  
30 that is often overlooked, and is a significant difference from prior method. Many have not considered and have failed to see its importance in creating organ cultures with reproducible samples. Being able to create organ, organotypic, or histotypic cultures by using the exact same  
35 assembly procedures with reliability will revolutionize the

pharmacological, food, and cosmetics testing industries. Organ cultures will be a much more reliable indicator of true drug behavior *in vivo* than current cytotoxicity testing methods. This will reduce greatly the cost of drug testing and manufacturing thereby lowering the cost of medication and health care costs. It will also reduce the amount of animal testing that is done as well. Organ cultures that can be compared with each other can provide insight into other fields as well such as molecular and cell biology, genetics, and tissue engineering.

In addition, direct cell deposition creates tissue structures that are more histologically accurate. That is, cells are placed next to other cells that they are normally next to within an *in vivo* environment. They can also be deposited in their proper location and ratios. This has huge significance, since cells do not exist alone, but rather, rely upon each other for proper function and maintenance. Cell-cell signaling and communication either from direct contact or paracrine signaling is vital for proper cellular behavior, differentiation, and proliferation. Also, the extracellular matrix produced by cells is vital for cellular function.

CAD integration capabilities of the methods and system of the present invention allow for the incorporation of non-biological elements into the design including, but not limited to, drug chambers, access ports, biotelemetry for doctors and biosensors. These non-biomimetic features can be created in CAD, as shown for example in Figure 6, saved as a part, and then reused over and over, being incorporated into many different designs. Thus, integration of CAD in the process of the present invention enables not just the building of devices that imitate nature, but also the building of devices that can assist or go beyond nature.

The multi-nozzle system with different types of nozzles used in the methods and system of the present invention permits layering of multiple components into the device. Nozzles could be different in sizes, diameters, 5 tip types, or in different operational mechanisms, such as solenoid, piezoelectric, and pneumatic air-regulated nozzles. For example, one nozzle can be specialized for cell deposition, while another nozzle can be optimized for depositing viscous structural members.

10 As shown in Figure 1, implementation of the method and apparatus of system of the present invention involves use of an automatic control system, including a computer with software for CAD and medical imaging process ability to perform Boolean operations, mirroring, smoothing and 15 three-dimensional reconstruction from MRI/CT to tissue replacement model; a XYZ positioning system inclusive of motion controllers and motors with an XYZ axis; a multi-nozzle system preferably comprising at least a microdroplet/fine resolution nozzle and a high 20 viscosity/extrusion nozzle, as well as nozzle controllers, fluid reservoirs, and filters; and a pressure system inclusive of pressure tanks, pressure chambers, compressor/vacuum pumps, pressure sensors, and regulators.

In addition to the above-preferred embodiment, 25 alternative variations of the methods and system are possible.

In one embodiment, a device can be constructed by either moving the platform that the device is being constructed on, or by moving the print head, or by a 30 combination of both through controlling the XYZ positioning system.

Alternative nozzles or other devices can also be used to provide various coating or washings. For example, biochemical surface treatment can be performed via a nozzle 35 or other device, for example, by washing, spraying, etc.,

simultaneously with the deposition of scaffolding materials through other nozzle(s). A coating material can also be sprayed on the device simultaneously with the deposition of the scaffolding material through other nozzle(s), or a  
5 coating material can be sprayed onto a single layer or layers of the device. An additional nozzle or other device can also be used to add a support material or temporary scaffolding that can later be removed from the finished part, for example, a reversible gel, simultaneously with  
10 the deposition of the scaffolding material through other nozzle(s). An additional nozzle can also be used to deposit drops-on-demand drugs, or lines of powder or solid materials, simultaneously with the deposition of the scaffolding material through other nozzle(s). An  
15 additional nozzle can also be used to deliver energy to speed the scaffold solidification, for example, to transmit a UV or Laser through an optical fiber simultaneously with the deposition of the scaffolding material through other nozzle(s). An additional nozzle can also be used to  
20 deposit, extrude or pattern electrically conductive materials within the scaffold simultaneously with the deposition of the scaffolding material through other nozzle(s) to generate wired, circuited, or biochip embedded scaffolds. An additional nozzle can also be used to  
25 transmit/deposit fluid simultaneously with the deposition of the scaffolding material through other nozzle(s). The fluid can be applied to the part for various purposes such as cooling, sterilization, cross-linking, solidification, etc. When using fluids, the part can be created in a  
30 container capable of holding fluids (a dish, a culture plate well, a fluid tank, etc.). The fluid level can be incremented by the same height as the layer being formed, thus raising the fluid level, or, the height level of the part could be decremented, thus lowering it into the fluid.

In-situ sterilization can be incorporated into the method of the present invention as well and can be done in several ways. In one embodiment, a solution with antibiotics such as penicillin is added through the multi-  
5 nozzle deposition system while making the device or afterwards. In another embodiment, a sterilizing solution (non-antibiotic) is added to one of the nozzles for deposition or post-sterilization. An alternative device to a nozzle, as part of the multi-nozzle deposition system,  
10 can also be used such as device emitting ultraviolet radiation, heat, or gamma irradiation.

The method and system of the present invention may further comprise imaging capabilities such as an ultrasonic transducer that can be used for imaging the device while it  
15 is being built. Alternatively, an optical imaging apparatus, such as a microscope, can be used to provide visual information, or provide data for feedback in a closed-loop control system. An optical imaging apparatus can also be used to monitor fluorescence and reporter gene  
20 activities which can be used for cell counting, calculating the presence of proteins, DNA expression, metabolic activity, cell migration, etc. Atomic force microscopy and scanning tunneling microscopy, can also provide information about the device at nanoscale resolution.

25 Sensing devices can also be incorporated into the methods and system to provide relevant data such as temperature, or to monitor chemical reactions, chemicals released during production, and/or mechanical forces such as shear during production. Such sensing devices can be  
30 used to create a feedback control mechanism to regulate the process parameters in an automated fashion.

Mechanical agitation or stimulation devices such as ultrasonic, subsonic, and/or sonic transducers can also be incorporated into the methods and system to stimulate the  
35 device mechanically during construction. The stimulations

will help to improve the device structural properties, for example, homogeneity of the cell and scaffolding material distribution.

Further, mechanical devices can be used to stamp,  
5 press, adjust, move, cut, and trim the device during construction.

Thus, the methods and system of the present invention comprise multiple steps and elements that, when combined, create a very powerful and robust method and system for  
10 manufacturing devices within the biological field, as well as other fields outside of biology. For example, devices produced in accordance with the methods and system described can be used as reproducible organ cultures. Such organ cultures are expected to be very useful in  
15 cytotoxicity testing (i.e. food, drug, and cosmetics industry), and other fields such as the study of tissue engineering, molecular biology, and cell biology. The greatly improved reproducibility between samples of organ cultures is achieved using the method and system of the  
20 present invention by directly depositing cells and biological factors while building the device. If one relies upon inward cell migration into the completed tissue scaffold or construct, there is no consistency in the location, distribution, or ratios of the cells. With the  
25 automated methods and system of the present invention, reproducibility between heterogeneous, 3-dimensional organ cultures is achieved. The cells, biological factors, and scaffold materials can be precisely deposited in the same locations, in the same manner, and with the same  
30 concentrations. This results in organ cultures that are assembled in the exact same manner, and so can be used to make comparisons between different organ culture test samples. In addition, direct cell deposition using the methods and system of the present invention permits  
35 creation of tissue engineering devices that are more

natural histologically. Cells can be placed next to other cells in a spatial pattern and orientation similar to their *in vivo* environment. They can also be deposited in their proper ratios, thus resulting in a much better tissue  
5 scaffold than produced currently.

Additional ramifications of the methods and system of the present invention include scaling up and mass production. The introduction of computer-aided design and automated assembly allows for mass production of tissue  
10 samples, cultures, and organs, that can be used for pharmacological testing, for example, in testing hundreds of variations of cancer-fighting drugs. Automation can lead to not only increased design complexity, but also increased speed, consistency, and quality control.

15 The following nonlimiting examples are provided to further illustrate the present invention.

#### Examples

The apparatus depicted in Figure 2 was used to  
20 construct various three-dimensional biopolymer based tissue scaffolds.

For example, shown in Figure 7 are, several three-dimensional hydrogel scaffolds (10 layers, calcium alginate), extruded as a 3% (w/v) alginate filament within  
25 a cross-linking solution (Figure 3a) and simple alginate geometrical pattern (Figure 3b). Depending upon the size of the syringe nozzle, the pressures used, and the type of deposition method (extrusion), alginate filaments within the 30-40 micron range (Figure 3c) were created for 3%  
30 (w/v) sodium alginate solution with a 5% (w/v) calcium chloride cross-linking solution, at 0.50 psi.

Further, cell deposition/extrusion studies were conducted by extruding alginate hydrogel mixed with human endothelial cells at a cell concentration: 750,000 cells/ml  
35 with sodium alginate: 1.5% (w/v), nozzle: EFD 200  $\mu$ m at

pressure: 2 psi, deposition speed: 10 mm/s, and calcium chloride: 5% (w/v) (see Figure 4). Experiments were also preformed testing multi-nozzle heterogeneous deposition of different materials. As shown in Figure 5, a variety of materials were simultaneously deposited, containing different alginate solutions at concentrations in the range of 0.1% - 0.4% (w/v), with the light gray material designated by A also containing an alginate microspheres suspension and a darker gray chitosan hydrogel designated as B.

**What is Claimed is:**

1. A process for manufacturing complex parts and devices comprising:
  - (a) utilizing a CAD environment to design a part or  
5 device to be created;
  - (b) converting the CAD designed part or device into a heterogeneous material and multi-part assembly model which can be used for multi-nozzle printing; and
  - (c) printing the designed part or device using  
10 different, specialized nozzles.
2. The process of claim 1 further comprising using Boolean, scaling, smoothing, mirroring, or other operations to modify the CAD design prior to conversion into a  
15 heterogeneous material and multi-part assembly model.
3. The process of claim 1 wherein in step (a) data taken from MRI, CT or other patient specific data is imported into the CAD environment to design the part or  
20 device to be created.
4. The process of claim 1 wherein a biomimetic and non-biomimetic feature is designed into the part or device.
- 25 5. The process of claim 1 wherein the part or device comprises a tissue engineering device and printing in step (d) involves direct deposition of cells or biological factors.
- 30 6. The process of claim 5 wherein direct cell deposition improves histological accuracy, cell ratios, and spatial patterning of cells in the part or device.
7. The process of claim 1 wherein the part or device  
35 produced comprises an artificial organ, a tissue scaffold,

an artificial vasculature or channel system, or a sample for cytotoxicity testing.

8. The process of claim 1 wherein the part or device produced comprises a biochip, biosensor, bionic,  
5 cybernetic, mechanoactive, or a bioactive tissue scaffold.

9. The process of claim 1 wherein the part or device is used in drug delivery.

10 10. A multi-nozzle biopolymer deposition apparatus comprising:

(a) a data processing system which processes a designed scaffold model and converts it into a layered process tool path;

15 (b) a motion control system driven by the layered process tool path; and

(c) a material delivery system comprising multiple nozzles of different types and sizes which deposits specified hydrogels with different viscosities thereby  
20 constructing a scaffold from the designed scaffold model.

1/4






FIG. 1

2 / 4




**FIG. 2**



**FIG. 3a**



**FIG. 3b**



**FIG. 3c**

3/4



**FIG. 4a**




**FIG. 4b**




**FIG. 4c**




**FIG. 4d**



**FIG. 5a**



**FIG. 5b**




**FIG. 5c**


4/4



**FIG. 6a**




**FIG. 6b**




**FIG. 6c**




**FIG. 6d**




**FIG. 7a**




**FIG. 7b**



**FIG. 7c**



**FIG. 8**



**FIG. 9**

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/15316

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : G06F 17/50; A01N 63/00; B29C 41/00

US CL : 703/1, 424/93.7, 264/40.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 703/1, 424/93.7, 264/40.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
ACM Portal, Proquest

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, B	US 6,772,026 B2 (Bradbury et al) 3 August 2004 (3.08.2004), FIGURES 1-13.	1-10
A	US 6,333,194 B1 (Levy et al) 25 December 2001, (25.12.2001) Col. 11 Lines 13-18.	1-10
A	US 6,143,293 A (Weiss et al) 7 November 2000 (7.11.2003), FIGURE 2.	1-10
A	US 6,547,994 B1 (Monkhouse et al) 15 April 2003 (15.04.2003), FIGURE 2.	1-10
A, P	US 6,730,252 B1 (Teoh et al) 4 May 2004 (4.05.2004) FIGURES 1-7.	1-10

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

04 March 2005 (04.03.2005)

Date of mailing of the international search report

22 MAR 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Kevin Teska

Telephone No. (571)272-1400